MeSH term
Frequency | Condition_Probility | Female | 265 | 0.0 |
Humans | 791 | 0.0 |
Pregnancy | 11 | 0.0 |
Acute Disease | 38 | 1.0 |
Child | 96 | 0.0 |
Child, Preschool | 78 | 0.0 |
Flow Cytometry | 12 | 0.0 |
Gene Expression Regulation, Neoplastic | 39 | 1.0 |
Male | 272 | 0.0 |
Neoplasm, Residual | 8 | 9.0 |
Polymerase Chain Reaction | 93 | 0.0 |
Predictive Value of Tests | 8 | 0.0 |
Prognosis | 30 | 0.0 |
Research Support, Non-U.S. Gov't | 472 | 0.0 |
Sensitivity and Specificity | 13 | 0.0 |
WT1 Proteins/analysis/*genetics | 4 | 100.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
*Glycoproteins | 7 | 0.0 |
Immunoenzyme Techniques | 15 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Ovarian Neoplasms/*metabolism/pathology | 3 | 4.0 |
Tumor Markers, Biological/metabolism | 8 | 2.0 |
WT1 Proteins/*metabolism | 12 | 100.0 |
Amino Acid Substitution | 5 | 0.0 |
Animals | 233 | 0.0 |
Base Sequence | 195 | 0.0 |
COS Cells | 15 | 0.0 |
Cell Line | 76 | 0.0 |
Cell Line, Transformed | 12 | 0.0 |
Cercopithecus aethiops | 7 | 0.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Gene Expression Regulation/*genetics | 3 | 2.0 |
Genes, Dominant | 5 | 0.0 |
*Genes, Wilms Tumor | 179 | 94.0 |
Kidney/embryology | 6 | 18.0 |
Mesoderm/cytology | 3 | 8.0 |
Mice | 125 | 0.0 |
Molecular Sequence Data | 206 | 0.0 |
Point Mutation | 13 | 0.0 |
Species Specificity | 9 | 0.0 |
Transfection | 76 | 0.0 |
WT1 Proteins/chemistry/*physiology | 2 | 100.0 |
Adolescent | 75 | 0.0 |
Adult | 121 | 0.0 |
Aged | 64 | 0.0 |
English Abstract | 24 | 0.0 |
Genes, Wilms Tumor | 51 | 86.0 |
Leukemia/*genetics/metabolism | 2 | 22.0 |
Middle Aged | 79 | 0.0 |
RNA, Messenger/genetics | 22 | 0.0 |
WT1 Proteins/*biosynthesis/genetics | 6 | 100.0 |
Algorithms | 2 | 0.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
Cell Division | 26 | 0.0 |
Cell Separation | 4 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Epitopes | 2 | 0.0 |
Immunophenotyping | 9 | 0.0 |
Protein Binding | 20 | 0.0 |
Software | 2 | 0.0 |
Aged, 80 and over | 23 | 0.0 |
Alleles | 27 | 0.0 |
Bone Marrow/metabolism | 5 | 4.0 |
Case-Control Studies | 10 | 0.0 |
Japan | 10 | 0.0 |
WT1 Proteins/*genetics | 35 | 100.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Mutation/*genetics | 14 | 1.0 |
Neoplasms, Germ Cell and Embryonal/genetics/pathology | 2 | 66.0 |
Phenotype | 32 | 0.0 |
Gene Expression Regulation | 23 | 0.0 |
Transcription Factors/genetics/*metabolism | 16 | 2.0 |
Feasibility Studies | 2 | 0.0 |
Infant | 67 | 1.0 |
Infant, Newborn | 22 | 0.0 |
Neoplasm, Residual/*diagnosis | 8 | 18.0 |
Prospective Studies | 4 | 0.0 |
RNA, Messenger/metabolism | 16 | 0.0 |
RNA, Neoplasm/analysis | 13 | 4.0 |
Reverse Transcriptase Polymerase Chain Reaction | 59 | 0.0 |
Tumor Markers, Biological/analysis | 9 | 1.0 |
Embryonic and Fetal Development/genetics | 6 | 6.0 |
Ovary/embryology | 3 | 23.0 |
*Sex Determination (Genetics) | 11 | 20.0 |
Testis/embryology | 3 | 13.0 |
X Chromosome | 2 | 0.0 |
Y Chromosome | 2 | 2.0 |
High Mobility Group Proteins/*genetics | 4 | 4.0 |
Sex Determination (Genetics) | 10 | 27.0 |
Sex Differentiation/*genetics | 5 | 18.0 |
Testis/*embryology | 2 | 20.0 |
Transcription Factors/*genetics | 86 | 4.0 |
Apoptosis/genetics | 3 | 1.0 |
Follow-Up Studies | 14 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Survival Analysis | 6 | 0.0 |
Treatment Outcome | 16 | 0.0 |
Bone Marrow Transplantation | 6 | 2.0 |
Chimera/genetics | 2 | 5.0 |
Gene Expression | 55 | 0.0 |
Fishes | 2 | 2.0 |
Gene Expression Regulation, Developmental | 17 | 1.0 |
Mammals | 3 | 0.0 |
Promoter Regions (Genetics) | 55 | 1.0 |
Sertoli Cells/metabolism | 6 | 30.0 |
Testicular Hormones/*genetics | 2 | 14.0 |
Carcinoma, Small Cell/*metabolism | 2 | 8.0 |
Diagnosis, Differential | 22 | 1.0 |
Immunohistochemistry | 54 | 0.0 |
Biopsy | 3 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 6 | 1.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
Comparative Study | 56 | 0.0 |
Protein p53/analysis | 2 | 0.0 |
WT1 Proteins/*analysis/genetics | 2 | 100.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Zinc Fingers | 43 | 8.0 |
Chromosome Deletion | 12 | 1.0 |
Chromosomes, Human, Pair 11/genetics | 14 | 6.0 |
Homeodomain Proteins/genetics | 4 | 1.0 |
In Situ Hybridization, Fluorescence | 11 | 0.0 |
Karyotyping | 24 | 1.0 |
Nephroblastoma/*genetics/pathology | 18 | 66.0 |
Translocation, Genetic | 17 | 2.0 |
WT1 Proteins/genetics | 6 | 60.0 |
Cell Transformation, Viral | 2 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 10 | 0.0 |
X Chromosome/genetics | 3 | 1.0 |
Genes, Wilms Tumor/*physiology | 12 | 100.0 |
Hematopoietic Stem Cells/*metabolism | 3 | 2.0 |
RNA, Messenger/analysis | 30 | 0.0 |
Recurrence | 10 | 0.0 |
Remission Induction | 8 | 1.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 3 | 5.0 |
Transplantation, Autologous | 2 | 0.0 |
3T3 Cells | 19 | 0.0 |
Binding Sites | 50 | 0.0 |
Blotting, Western | 22 | 0.0 |
Cell Cycle | 5 | 0.0 |
Cyclins/metabolism | 2 | 0.0 |
Down-Regulation | 12 | 0.0 |
G1 Phase | 2 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Mutagenesis, Site-Directed | 12 | 0.0 |
Phosphorylation | 7 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Isoforms | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 187 | 0.0 |
*Transcription, Genetic | 19 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Gene Deletion | 20 | 1.0 |
*Gene Expression Regulation | 20 | 1.0 |
Oncogene Proteins, Fusion/*genetics | 3 | 1.0 |
Promoter Regions (Genetics)/genetics | 9 | 0.0 |
Transcription, Genetic | 41 | 0.0 |
Chromosomes, Artificial, Yeast | 6 | 1.0 |
Genetic Complementation Test | 3 | 0.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mice, Knockout | 8 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
*Nephroblastoma | 2 | 100.0 |
Stem Cells/cytology | 3 | 4.0 |
Trans-Activation (Genetics) | 21 | 1.0 |
Transcription Factors/genetics | 23 | 2.0 |
Tumor Cells, Cultured | 93 | 0.0 |
WT1 Proteins/genetics/*metabolism | 11 | 100.0 |
CA-125 Antigen/analysis | 2 | 10.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
*Immunophenotyping | 2 | 1.0 |
Intermediate Filament Proteins/analysis | 2 | 5.0 |
Keratin/analysis | 7 | 3.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Transcription Factors/analysis | 3 | 4.0 |
WT1 Proteins/analysis | 4 | 80.0 |
Beckwith-Wiedemann Syndrome/genetics | 7 | 33.0 |
Chromosomes, Human, Pair 1 | 5 | 2.0 |
Genes, p53 | 12 | 2.0 |
Kidney Neoplasms/*genetics | 65 | 31.0 |
*Trans-Activators | 2 | 0.0 |
WAGR Syndrome/genetics | 3 | 60.0 |
DNA-Binding Proteins/*analysis | 10 | 16.0 |
Kidney/pathology | 7 | 4.0 |
Transcription Factors/*analysis | 8 | 14.0 |
WT1 Proteins/*analysis | 2 | 100.0 |
*Gene Expression Regulation, Leukemic | 7 | 8.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
*Nuclear Proteins | 21 | 1.0 |
Up-Regulation | 8 | 0.0 |
Breast/metabolism | 2 | 2.0 |
In Situ Hybridization | 24 | 0.0 |
Oncogenes | 4 | 1.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 23 | 0.0 |
WT1 Proteins/genetics/metabolism | 3 | 100.0 |
*Antigens, CD34 | 2 | 2.0 |
Flow Cytometry/methods | 2 | 0.0 |
Leukemia/*genetics | 8 | 6.0 |
Polymerase Chain Reaction/methods | 11 | 0.0 |
Age Factors | 4 | 0.0 |
CpG Islands/*genetics | 2 | 2.0 |
DNA-Binding Proteins/metabolism | 8 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Protein p16/metabolism | 2 | 3.0 |
T-Lymphocytes, Cytotoxic/*immunology | 8 | 1.0 |
WT1 Proteins/genetics/*immunology | 2 | 100.0 |
Amino Acid Sequence | 83 | 0.0 |
Binding Sites/genetics | 5 | 0.0 |
Chromosome Banding | 12 | 1.0 |
Chromosome Mapping | 33 | 0.0 |
Cloning, Molecular | 25 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
DNA/chemistry/genetics | 3 | 0.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Rats | 27 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Analysis, DNA | 13 | 0.0 |
Sequence Homology, Amino Acid | 19 | 0.0 |
Telomerase/*genetics | 3 | 10.0 |
Transcription Factors/metabolism | 11 | 0.0 |
Xenopus | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Leukemia, Myelocytic, Acute/*genetics | 4 | 3.0 |
Myelodysplastic Syndromes/*genetics | 2 | 2.0 |
Alternative Splicing | 22 | 2.0 |
DNA Mutational Analysis | 28 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 3 | 1.0 |
Zinc Fingers/genetics | 20 | 11.0 |
Binding Sites/physiology | 2 | 1.0 |
Denys-Drash Syndrome/genetics | 3 | 100.0 |
Gene Expression Profiling | 9 | 0.0 |
Kidney/cytology/metabolism | 2 | 2.0 |
Nephroblastoma/genetics | 35 | 62.0 |
Promoter Regions (Genetics)/*physiology | 2 | 2.0 |
Structure-Activity Relationship | 3 | 0.0 |
Trans-Activation (Genetics)/*physiology | 3 | 2.0 |
*Chromosome Deletion | 16 | 2.0 |
Chromosomes, Human, Pair 12/*genetics | 2 | 1.0 |
DNA/genetics | 8 | 0.0 |
Family Health | 2 | 0.0 |
Genotype | 16 | 0.0 |
Lod Score | 2 | 0.0 |
Microsatellite Repeats | 7 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Cell Division/*drug effects | 3 | 1.0 |
Fetal Blood/cytology | 2 | 1.0 |
Gene Expression/physiology | 4 | 1.0 |
Genetic Vectors | 9 | 0.0 |
Retroviridae/genetics | 4 | 1.0 |
Transduction, Genetic | 2 | 0.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
Databases, Factual | 3 | 1.0 |
*Gene Deletion | 9 | 1.0 |
*Gene Expression Regulation, Developmental | 11 | 1.0 |
Nucleic Acid Hybridization | 7 | 0.0 |
Pedigree | 15 | 0.0 |
Y Chromosome/*genetics | 2 | 2.0 |
Chromosome Aberrations | 6 | 1.0 |
*Chromosomes, Human, Pair 11 | 35 | 5.0 |
Homozygote | 10 | 0.0 |
*Loss of Heterozygosity | 3 | 0.0 |
*Mutation | 31 | 0.0 |
Cells, Cultured | 18 | 0.0 |
Decidua/physiology | 2 | 25.0 |
*Gene Expression | 10 | 0.0 |
WT1 Proteins/metabolism | 7 | 87.0 |
Mutation | 59 | 0.0 |
WT1 Proteins/genetics/*physiology | 3 | 100.0 |
Antigens, CD34/metabolism | 2 | 0.0 |
DNA Primers/chemistry | 10 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 11 | 2.0 |
Drug Resistance, Multiple | 2 | 1.0 |
*Immediate-Early Proteins | 22 | 9.0 |
Transcription Factors/genetics/metabolism | 11 | 2.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Exons | 38 | 0.0 |
Introns | 14 | 0.0 |
Tissue Distribution | 6 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 16 | 1.0 |
Models, Biological | 8 | 0.0 |
Mutation/genetics | 8 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 11 | 0.0 |
Blast Crisis | 3 | 8.0 |
Cell Division/drug effects | 4 | 0.0 |
HL-60 Cells/pathology | 2 | 25.0 |
K562 Cells/pathology | 2 | 50.0 |
Oligonucleotides, Antisense/*pharmacology | 2 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 6 | 1.0 |
Cell Differentiation | 21 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 9 | 1.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Sialoglycoproteins/*genetics | 2 | 3.0 |
*Zinc Fingers | 16 | 7.0 |
Immunotherapy/*methods | 3 | 2.0 |
Neoplasm Staging | 10 | 0.0 |
*Alternative Splicing | 10 | 1.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Kidney/cytology | 4 | 2.0 |
Receptor, IGF Type 1/*genetics | 6 | 25.0 |
Transcription Factor, Sp1/*metabolism | 3 | 0.0 |
Zinc Fingers/physiology | 5 | 21.0 |
DNA Primers | 32 | 0.0 |
K562 Cells | 9 | 2.0 |
Kinetics | 7 | 0.0 |
Models, Genetic | 7 | 0.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Substrate Specificity | 2 | 0.0 |
*Apoptosis | 7 | 0.0 |
Oligonucleotides, Antisense | 3 | 3.0 |
WT1 Proteins/*biosynthesis | 8 | 100.0 |
Drug Resistance, Neoplasm/*genetics | 3 | 3.0 |
DNA-Binding Proteins/*genetics/physiology | 7 | 8.0 |
Transcription Factors/*genetics/physiology | 7 | 7.0 |
WT1 Proteins | 278 | 95.0 |
High Mobility Group Proteins/genetics | 2 | 5.0 |
Cyclins/*genetics/metabolism | 2 | 4.0 |
Tretinoin/pharmacology | 5 | 1.0 |
WT1 Proteins/*genetics/metabolism | 9 | 100.0 |
Cell Nucleus/*chemistry | 2 | 5.0 |
Apoptosis | 6 | 0.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Fusion Proteins, bcr-abl/genetics | 2 | 4.0 |
*Gene Expression Regulation, Neoplastic | 30 | 2.0 |
In Vitro | 9 | 0.0 |
Piperazines/*therapeutic use | 2 | 4.0 |
Pyrimidines/*therapeutic use | 2 | 4.0 |
RNA, Messenger/*analysis | 8 | 1.0 |
RNA, Neoplasm/genetics | 10 | 2.0 |
Leukemia, Lymphocytic, Acute/genetics | 3 | 10.0 |
Neoplasm, Residual/*genetics | 2 | 50.0 |
Transplantation, Homologous | 5 | 0.0 |
Tumor Markers, Biological | 5 | 1.0 |
Kidney Neoplasms/*genetics/pathology | 14 | 18.0 |
Polymorphism, Genetic | 13 | 0.0 |
Urogenital Abnormalities/*genetics | 6 | 40.0 |
Genes, Wilms Tumor/*genetics | 60 | 95.0 |
Kidney Transplantation | 4 | 3.0 |
Syndrome | 53 | 2.0 |
*Drosophila Proteins | 3 | 0.0 |
Genes, Retinoblastoma | 4 | 4.0 |
*Germ-Line Mutation | 2 | 0.0 |
Loss of Heterozygosity | 9 | 1.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics | 5 | 0.0 |
Chromosomes, Human, Pair 11 | 39 | 10.0 |
Fetus | 6 | 1.0 |
DNA-Binding Proteins/*genetics | 95 | 4.0 |
Neoplasm Proteins/genetics | 6 | 1.0 |
Oncogene Proteins, Fusion/genetics | 4 | 4.0 |
Cell Transformation, Neoplastic/genetics | 8 | 2.0 |
*Genetic Techniques | 2 | 3.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Biological Markers | 5 | 0.0 |
DNA-Binding Proteins/genetics | 25 | 3.0 |
Repressor Proteins/genetics | 3 | 2.0 |
DNA-Binding Proteins/analysis/*immunology | 2 | 100.0 |
Transcription Factors/analysis/*immunology | 2 | 66.0 |
Biopsy, Needle | 2 | 0.0 |
Oncogene Proteins, Fusion/analysis/genetics | 2 | 40.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
DNA Primers/genetics | 9 | 0.0 |
Risk Factors | 5 | 0.0 |
*Evolution, Molecular | 3 | 0.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Genomic Imprinting/*genetics | 2 | 2.0 |
Insulin-Like Growth Factor II/genetics | 3 | 3.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Proteins/genetics | 4 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Cadherins/*genetics | 2 | 2.0 |
CpG Islands | 4 | 1.0 |
DNA Methylation | 5 | 0.0 |
*Genes, Tumor Suppressor | 36 | 3.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 3 | 2.0 |
*Chromosomes, Human, Pair 13 | 3 | 1.0 |
Genes, Tumor Suppressor/genetics | 3 | 1.0 |
Loss of Heterozygosity/genetics | 3 | 2.0 |
Neoplasms/*genetics | 4 | 1.0 |
Blotting, Northern | 33 | 0.0 |
DNA Fragmentation | 2 | 0.0 |
Embryo/physiology | 4 | 11.0 |
Retinoblastoma | 2 | 18.0 |
Fluorescent Antibody Technique | 12 | 0.0 |
Kidney Glomerulus/*pathology | 2 | 10.0 |
Membrane Glycoproteins/metabolism | 3 | 0.0 |
Time Factors | 14 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 5 | 2.0 |
DNA | 7 | 0.0 |
*RNA | 2 | 6.0 |
Kidney Neoplasms/*genetics/*pathology | 2 | 28.0 |
DNA-Binding Proteins/*physiology | 10 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Nephroblastoma/*genetics/*pathology | 4 | 100.0 |
Plasmids | 5 | 0.0 |
Receptors, Calcitriol/*biosynthesis/genetics | 2 | 28.0 |
Transcription Factors/*physiology | 10 | 2.0 |
DNA-Binding Proteins/*genetics/*physiology | 2 | 5.0 |
Transcription Factors/*genetics/*physiology | 2 | 7.0 |
Base Sequence/genetics | 4 | 1.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Antigens, Surface/analysis | 3 | 0.0 |
DNA-Binding Proteins/analysis | 3 | 3.0 |
Tumor Markers, Biological/*analysis | 14 | 1.0 |
DNA/metabolism | 12 | 0.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 4 | 2.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Kidney Neoplasms/genetics | 23 | 31.0 |
Magnesium/metabolism | 2 | 2.0 |
Nucleic Acid Conformation | 2 | 0.0 |
RNA/metabolism | 5 | 1.0 |
Transcription Factors/chemistry/genetics/*metabolism | 3 | 2.0 |
*Immunohistochemistry | 3 | 3.0 |
Subcellular Fractions | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 14 | 0.0 |
Enhancer Elements (Genetics) | 5 | 1.0 |
Gonadal Dysgenesis/genetics | 4 | 66.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
DNA-Binding Proteins/*immunology | 2 | 8.0 |
Transcription Factors/*immunology | 2 | 14.0 |
DNA-Binding Proteins/biosynthesis/genetics/*physiology | 2 | 5.0 |
Genes, Reporter | 17 | 0.0 |
Kidney/metabolism | 13 | 3.0 |
Response Elements | 2 | 0.0 |
Signal Transduction | 8 | 0.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Mutagenesis | 6 | 0.0 |
Repressor Proteins/*genetics | 5 | 1.0 |
Zinc Fingers/*genetics | 18 | 9.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Hematopoietic Stem Cells/*cytology | 3 | 1.0 |
Luciferases/genetics | 5 | 1.0 |
Recombinant Proteins/biosynthesis | 6 | 1.0 |
*Trans-Activation (Genetics) | 11 | 1.0 |
Trans-Activators/genetics/*metabolism | 3 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 4 | 2.0 |
Hela Cells | 15 | 0.0 |
*Promoter Regions (Genetics) | 26 | 1.0 |
Pseudohermaphroditism/genetics | 8 | 57.0 |
Transcription Factors/*metabolism | 21 | 1.0 |
HL-60 Cells | 5 | 0.0 |
Fatal Outcome | 4 | 0.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Glomerular Mesangium/*pathology | 3 | 37.0 |
*Point Mutation | 16 | 1.0 |
Sclerosis | 5 | 9.0 |
Disease Models, Animal | 6 | 0.0 |
Germ-Line Mutation | 6 | 1.0 |
Gonads/embryology | 4 | 50.0 |
Leukemia/genetics | 3 | 7.0 |
Nephroblastoma/*genetics | 107 | 71.0 |
RNA Processing, Post-Transcriptional | 4 | 3.0 |
Codon | 3 | 0.0 |
Genes, Wilms Tumor/genetics | 19 | 82.0 |
Genitalia, Female/*abnormalities | 2 | 40.0 |
Heterozygote | 18 | 0.0 |
Kidney Diseases/*genetics | 7 | 19.0 |
Mutation, Missense | 3 | 0.0 |
*DNA Methylation | 7 | 1.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 7 | 7.0 |
Transcription Factors/*biosynthesis/genetics | 6 | 6.0 |
Cohort Studies | 5 | 0.0 |
Retrospective Studies | 9 | 0.0 |
Adrenal Glands/*embryology | 2 | 40.0 |
Animals, Genetically Modified | 2 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 4 | 1.0 |
Embryonic and Fetal Development | 6 | 1.0 |
Gonads/*embryology | 5 | 55.0 |
Transcription Factors/genetics/*physiology | 3 | 1.0 |
Disease Progression | 11 | 0.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Cell Line, Tumor | 12 | 0.0 |
*Genes, myc | 3 | 1.0 |
Protein Biosynthesis | 6 | 0.0 |
Apoptosis/physiology | 5 | 1.0 |
DNA-Binding Proteins/chemistry/*genetics/metabolism | 2 | 4.0 |
Protein Conformation | 2 | 0.0 |
Protein Isoforms/physiology | 2 | 5.0 |
Transcription Factors/chemistry/*genetics/metabolism | 2 | 4.0 |
DNA-Binding Proteins/analysis/*genetics | 3 | 10.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Mice, Nude | 11 | 0.0 |
Simian virus 40/genetics | 2 | 1.0 |
Transcription Factors/analysis/*genetics | 3 | 9.0 |
Transplantation, Heterologous | 4 | 0.0 |
Abnormalities/genetics | 2 | 10.0 |
Cytoskeletal Proteins/*genetics | 2 | 1.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 17 | 4.0 |
Hematopoiesis/physiology | 2 | 4.0 |
Protein Isoforms/genetics/metabolism | 3 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 7 | 0.0 |
Transcription Factors/*genetics/metabolism | 14 | 4.0 |
Prostatic Neoplasms/*genetics | 2 | 1.0 |
RNA, Neoplasm/genetics/metabolism | 4 | 2.0 |
Embryonic and Fetal Development/physiology | 3 | 3.0 |
Genes, Wilms Tumor/*genetics/*physiology | 2 | 100.0 |
Kidney/*embryology | 6 | 20.0 |
Kidney Diseases/genetics | 4 | 28.0 |
RNA Editing | 2 | 11.0 |
Blotting, Southern | 22 | 0.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 20 | 0.0 |
Kidney Neoplasms/*genetics/metabolism | 7 | 25.0 |
Nephroblastoma/*genetics/metabolism | 8 | 57.0 |
Organ Specificity | 5 | 0.0 |
Kidney/*embryology/metabolism | 3 | 37.0 |
*Oncogenes | 5 | 1.0 |
Abdominal Neoplasms/*genetics | 3 | 50.0 |
Carcinoma, Small Cell/*genetics | 2 | 3.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Trans-Activation (Genetics)/physiology | 2 | 2.0 |
DNA, Neoplasm/analysis | 14 | 1.0 |
*Antigens, Neoplasm | 2 | 1.0 |
Nephroblastoma | 3 | 50.0 |
Chromosomes, Human, Pair 22 | 7 | 4.0 |
DNA, Neoplasm | 3 | 2.0 |
*Repressor Proteins | 11 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 3 | 0.0 |
Leukemia, Myeloid/*immunology | 3 | 7.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
DNA-Binding Proteins/*genetics/*immunology | 2 | 66.0 |
Transcription Factors/*genetics/*immunology | 2 | 100.0 |
*Microsatellite Repeats | 4 | 1.0 |
Chromosome Disorders | 4 | 1.0 |
Genomic Imprinting | 2 | 1.0 |
*RNA, Untranslated | 2 | 1.0 |
Transcription Factors | 2 | 2.0 |
K562 Cells/metabolism | 2 | 22.0 |
Genetic Markers | 19 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Combined Modality Therapy | 3 | 0.0 |
Incidence | 3 | 0.0 |
Prevalence | 2 | 0.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
T-Lymphocytes/*immunology | 6 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 3 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Genes, Reporter/genetics | 3 | 1.0 |
Precipitin Tests | 4 | 0.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 3 | 1.0 |
src Homology Domains | 2 | 0.0 |
*Genomic Imprinting | 3 | 1.0 |
Kidney/embryology/metabolism | 8 | 22.0 |
Methylation | 3 | 0.0 |
Leukemia/*diagnosis/genetics | 3 | 100.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
RNA Splicing | 7 | 1.0 |
Adenocarcinoma, Clear Cell/genetics | 2 | 15.0 |
Epithelium/chemistry | 2 | 1.0 |
Antigens, Surface/metabolism | 2 | 1.0 |
Nephrectomy | 3 | 3.0 |
DNA-Binding Proteins/*biosynthesis | 8 | 6.0 |
Transcription Factors/*biosynthesis | 8 | 7.0 |
Conserved Sequence | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Nephrotic Syndrome/*genetics | 4 | 30.0 |
*Sex Reversal, Gonadal | 2 | 4.0 |
DNA-Binding Proteins/physiology | 3 | 1.0 |
Sex Reversal, Gonadal | 4 | 16.0 |
Transcription Factors/physiology | 3 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Ribonucleoproteins/*metabolism | 2 | 4.0 |
Cadherins/analysis | 2 | 6.0 |
Lung Neoplasms/chemistry/*diagnosis | 2 | 40.0 |
Mesothelioma/chemistry/*diagnosis | 2 | 40.0 |
Genes, Tumor Suppressor | 11 | 1.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 3 | 1.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Growth Inhibitors/*analysis | 2 | 15.0 |
Testicular Hormones/*analysis | 2 | 50.0 |
Exons/*genetics | 2 | 0.0 |
Tyrosine/genetics | 2 | 4.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
Receptors, Retinoic Acid/genetics | 5 | 5.0 |
In Situ Nick-End Labeling | 5 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Genes, Tumor Suppressor/*physiology | 5 | 4.0 |
Mice, SCID | 2 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
DNA-Binding Proteins/*analysis/genetics | 3 | 14.0 |
Leukemia/diagnosis/*genetics | 2 | 50.0 |
Quality Control | 2 | 1.0 |
Transcription Factors/*analysis/genetics | 2 | 12.0 |
Gonadoblastoma/genetics | 3 | 100.0 |
Kidney Glomerulus/pathology | 4 | 8.0 |
*RNA Splicing | 3 | 1.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
HLA-A2 Antigen/immunology/metabolism | 2 | 28.0 |
Leukocytes, Mononuclear/cytology/immunology | 2 | 4.0 |
Recombinant Fusion Proteins/*genetics | 2 | 5.0 |
Survival Rate | 7 | 0.0 |
Transcription, Genetic/*genetics | 7 | 3.0 |
WT1 Proteins/*genetics/*metabolism | 2 | 100.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Genes, Tumor Suppressor/*genetics | 4 | 1.0 |
Genes, p53/*genetics | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
Disease-Free Survival | 9 | 0.0 |
Graft Survival | 2 | 0.0 |
Myelodysplastic Syndromes/*therapy | 2 | 14.0 |
Kidney | 7 | 1.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Platelet-Derived Growth Factor/genetics | 5 | 15.0 |
Microscopy, Electron | 4 | 0.0 |
Swine | 3 | 0.0 |
*Chromosome Mapping | 5 | 0.0 |
*Databases, Factual | 2 | 3.0 |
Genome, Human | 3 | 0.0 |
Neoplasms/genetics | 5 | 4.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Leukemia/*immunology | 3 | 7.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Insulin-Like Growth Factor II/*genetics | 5 | 3.0 |
Liver Neoplasms | 2 | 0.0 |
Kidney Failure/genetics | 2 | 25.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Trans-Activation (Genetics)/*genetics | 3 | 3.0 |
Genes, abl | 3 | 8.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 9 | 7.0 |
RNA-Binding Protein EWS | 8 | 28.0 |
Platelet-Derived Growth Factor/*genetics | 4 | 12.0 |
Reference Values | 7 | 0.0 |
*Genes, p53 | 6 | 1.0 |
Restriction Mapping | 14 | 0.0 |
*Kidney Glomerulus | 2 | 40.0 |
Gene Expression Regulation, Neoplastic/*physiology | 5 | 3.0 |
Introns/genetics | 5 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
DNA/analysis | 2 | 0.0 |
*X Chromosome | 2 | 0.0 |
Immunotherapy | 4 | 1.0 |
Myelodysplastic Syndromes/genetics | 2 | 8.0 |
Testicular Neoplasms/*genetics/pathology | 3 | 27.0 |
CHO Cells | 4 | 0.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Mutation/*physiology | 3 | 2.0 |
DNA Footprinting | 3 | 1.0 |
Osteosarcoma/metabolism | 2 | 14.0 |
Response Elements/genetics | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Life Tables | 2 | 1.0 |
Neoplasm Proteins/*biosynthesis/genetics | 3 | 1.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Consensus Sequence | 14 | 1.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Cell Division/physiology | 5 | 0.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Carcinoma, Papillary/genetics | 2 | 13.0 |
*Ligases | 2 | 1.0 |
Nephroblastoma/genetics/metabolism | 4 | 57.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
DNA, Antisense/*genetics | 2 | 15.0 |
Desmin/analysis | 3 | 4.0 |
Phosphopyruvate Hydratase/analysis | 3 | 3.0 |
Vimentin/analysis | 2 | 0.0 |
Leukemia/*diagnosis | 3 | 30.0 |
DNA-Binding Proteins/genetics/physiology | 3 | 3.0 |
Transcription Factors/genetics/physiology | 3 | 4.0 |
Urogenital System/embryology | 2 | 40.0 |
*Apoptosis/drug effects | 2 | 1.0 |
Consensus Sequence/genetics | 2 | 4.0 |
DNA/genetics/metabolism | 4 | 1.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Kidney Neoplasms/genetics/metabolism | 2 | 16.0 |
Staurosporine/pharmacology | 2 | 1.0 |
Vincristine/pharmacology | 2 | 3.0 |
DNA-Binding Proteins/biosynthesis/genetics/*metabolism | 2 | 9.0 |
P-Glycoprotein/*genetics | 2 | 4.0 |
Transcription Factors/biosynthesis/genetics/*metabolism | 2 | 11.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Repressor Proteins/chemistry/genetics/*metabolism | 2 | 4.0 |
Trans-Activators/chemistry/genetics/*metabolism | 2 | 2.0 |
Cell Differentiation/physiology | 4 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
SUMO-1 Protein/*metabolism | 2 | 6.0 |
Cryptorchidism/genetics | 2 | 40.0 |
Genitalia/*abnormalities | 2 | 16.0 |
Hypospadias/genetics | 2 | 40.0 |
*Phenotype | 3 | 1.0 |
Receptors, Androgen/genetics | 3 | 5.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
DNA-Binding Proteins/genetics/metabolism/*physiology | 5 | 8.0 |
Transcription Factors/genetics/metabolism/*physiology | 4 | 7.0 |
Cell Extracts | 2 | 1.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Aneuploidy | 2 | 1.0 |
Chromosome Aberrations/*genetics | 3 | 2.0 |
Chromosomes, Human, Pair 11/*genetics | 7 | 2.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 9 | 7.0 |
Hybrid Cells | 3 | 0.0 |
Transcription Factors/biosynthesis/*genetics | 7 | 6.0 |
Neoplasms/*genetics/pathology | 2 | 5.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
Mesoderm/physiology | 3 | 8.0 |
Leukemia, Lymphocytic, Acute, L1/*genetics | 2 | 5.0 |
Leukemia, Myeloid/*genetics | 3 | 2.0 |
Sex Differentiation/physiology | 2 | 22.0 |
Gonadal Dysgenesis/*genetics | 6 | 42.0 |
Kidney Failure, Chronic/*genetics | 3 | 20.0 |
Nephroblastoma/complications/*genetics | 7 | 100.0 |
RNA Splicing/*genetics | 2 | 2.0 |
*Tumor Markers, Biological | 3 | 1.0 |
Genitalia, Male/*abnormalities | 4 | 44.0 |
Biological Markers/analysis | 2 | 0.0 |
Neoplasm, Residual/diagnosis | 4 | 28.0 |
Cancer Vaccines/*therapeutic use | 2 | 9.0 |
*Vaccination | 2 | 3.0 |
Receptors, Retinoic Acid/*genetics | 3 | 5.0 |
Bone Marrow/pathology | 3 | 0.0 |
*Chromosomes, Human, Pair 22 | 3 | 1.0 |
*Translocation, Genetic | 10 | 1.0 |
Carcinoma, Small Cell/*genetics/pathology | 2 | 9.0 |
Pancreatic Neoplasms/*genetics/pathology | 2 | 5.0 |
*Variation (Genetics) | 3 | 0.0 |
Cell Differentiation/genetics | 5 | 1.0 |
Glomerular Mesangium/pathology | 2 | 25.0 |
Glomerulosclerosis, Focal/*metabolism/pathology | 2 | 66.0 |
Chickens | 3 | 0.0 |
Granulosa Cells/chemistry | 2 | 10.0 |
Receptors, Retinoic Acid/genetics/physiology | 2 | 18.0 |
Genes, Wilms Tumor/genetics/*physiology | 4 | 100.0 |
Spermatogenesis/*genetics | 2 | 4.0 |
Antineoplastic Agents/therapeutic use | 4 | 1.0 |
Sarcoma, Ewing's/*genetics | 5 | 10.0 |
Sarcoma, Small Cell/*genetics | 2 | 100.0 |
Chromosomes, Human, Pair 17/genetics | 4 | 2.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Lymphoma/genetics/metabolism/pathology | 2 | 40.0 |
Nephroblastoma/genetics/metabolism/pathology | 2 | 100.0 |
Sarcoma, Ewing's/genetics/metabolism/pathology | 2 | 66.0 |
Reproducibility of Results | 4 | 0.0 |
RNA, Antisense/*genetics | 2 | 6.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Antigens, Neoplasm/*analysis | 3 | 0.0 |
Basement Membrane/ultrastructure | 3 | 13.0 |
Oncogene Proteins, Fusion/analysis | 2 | 25.0 |
Ribonucleoproteins/*genetics | 5 | 11.0 |
Aniridia/*genetics | 5 | 17.0 |
Eye Proteins/*genetics | 2 | 1.0 |
*Homeodomain Proteins | 5 | 1.0 |
Cosmids | 4 | 1.0 |
DNA-Binding Proteins/biosynthesis/chemistry/*genetics | 2 | 20.0 |
Transcription Factors/biosynthesis/chemistry/*genetics | 2 | 16.0 |
Sex Differentiation/genetics/physiology | 2 | 40.0 |
Y Chromosome/genetics | 2 | 6.0 |
Protein Isoforms/genetics/physiology | 2 | 8.0 |
Polymorphism, Restriction Fragment Length | 10 | 0.0 |
Kidney Neoplasms/genetics/*metabolism | 3 | 25.0 |
RNA, Neoplasm/metabolism | 2 | 2.0 |
Point Mutation/*genetics | 3 | 1.0 |
Transcription Factors/biosynthesis/genetics | 3 | 4.0 |
Dogs | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Chromosomes, Human, Pair 16/genetics | 4 | 4.0 |
Genes, Retinoblastoma/genetics | 3 | 9.0 |
Lymphoma/*genetics | 2 | 4.0 |
Repetitive Sequences, Nucleic Acid | 6 | 0.0 |
Abnormalities, Multiple/*genetics | 4 | 1.0 |
Genitalia/abnormalities | 2 | 16.0 |
Genetic Screening | 2 | 0.0 |
Kidney Neoplasms/diagnosis/*genetics | 2 | 33.0 |
Nephroblastoma/diagnosis/*genetics | 2 | 100.0 |
Genetic Heterogeneity | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Kidney/growth & development/*metabolism | 2 | 50.0 |
Nephroblastoma/*metabolism | 2 | 50.0 |
Pseudohermaphroditism/*genetics | 6 | 42.0 |
Aniridia/complications/*genetics | 2 | 100.0 |
Eye Proteins/genetics | 2 | 4.0 |
Kidney Neoplasms/complications/*genetics | 4 | 57.0 |
Risk Assessment | 3 | 0.0 |
DNA/*metabolism | 6 | 1.0 |
Protein Binding/genetics | 2 | 0.0 |
Sequence Deletion | 12 | 0.0 |
DNA, Complementary | 10 | 0.0 |
Oligodeoxyribonucleotides | 13 | 1.0 |
Genes, Wilms Tumor/physiology | 3 | 100.0 |
Ovary/chemistry/embryology | 2 | 100.0 |
Testis/chemistry/embryology | 2 | 66.0 |
Cell Differentiation/drug effects/genetics | 3 | 5.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 3 | 1.0 |
Trans-Activators/genetics | 2 | 0.0 |
Protein p53/*metabolism | 2 | 0.0 |
Proteins/*genetics | 4 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Translocation, Genetic/*genetics | 5 | 2.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
*Chromosomes, Human, Pair 10 | 2 | 1.0 |
Fetus/metabolism | 2 | 1.0 |
Insulin-Like Growth Factor II/biosynthesis/genetics | 3 | 42.0 |
Rats, Wistar | 2 | 0.0 |
Cholecalciferol/pharmacology | 2 | 6.0 |
Base Composition | 2 | 0.0 |
Exons/genetics | 7 | 0.0 |
Gene Expression Regulation, Developmental/*physiology | 2 | 1.0 |
Deoxyribonuclease I/metabolism | 4 | 2.0 |
Kidney/*metabolism | 2 | 1.0 |
DNA-Binding Proteins/biosynthesis/*genetics/physiology | 2 | 28.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Hematopoiesis/*genetics | 3 | 5.0 |
Point Mutation/genetics | 2 | 0.0 |
Ovarian Neoplasms/genetics | 2 | 1.0 |
*DNA-Binding Proteins | 2 | 0.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Colon/metabolism | 2 | 1.0 |
Tetracycline/pharmacology | 2 | 2.0 |
Antigens, CD34 | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Molecular Weight | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Nephroblastoma/*genetics/*metabolism | 2 | 66.0 |
Receptor, Epidermal Growth Factor/*metabolism | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Bone Marrow Cells | 4 | 0.0 |
*Cell Differentiation | 2 | 0.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
RNA, Neoplasm/*analysis | 4 | 9.0 |
*Alleles | 8 | 0.0 |
*Chromosome Aberrations | 8 | 1.0 |
Trisomy | 2 | 1.0 |
Leucine Zippers | 2 | 1.0 |
Recombinant Proteins | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Apoptosis/*genetics | 3 | 1.0 |
Cell Cycle/genetics | 2 | 1.0 |
Cell Division/genetics | 4 | 1.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Disease Susceptibility | 4 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
Abnormalities, Multiple/genetics | 4 | 4.0 |
Aniridia/genetics | 6 | 35.0 |
Mental Retardation/genetics | 3 | 2.0 |
Urogenital Abnormalities | 4 | 50.0 |
Pulmonary Gas Exchange | 2 | 8.0 |
*Heterozygote | 4 | 1.0 |
*Linkage (Genetics) | 2 | 0.0 |
Hematopoietic Stem Cells/cytology | 2 | 2.0 |
Genital Neoplasms, Female/*metabolism/pathology | 2 | 40.0 |
Carcinoma, Endometrioid/*metabolism/pathology | 2 | 28.0 |
Cystadenocarcinoma, Serous/*metabolism/pathology | 2 | 66.0 |
Protein p53/biosynthesis | 2 | 1.0 |
*CpG Islands | 2 | 2.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Chick Embryo | 2 | 0.0 |
Genes, Wilms Tumor/*genetics/physiology | 3 | 100.0 |
DNA Probes | 6 | 0.0 |
Chromosomes, Human, Pair 22/*genetics | 2 | 2.0 |
*DNA Transposable Elements | 2 | 3.0 |
Sarcoma, Small Cell/*genetics/pathology | 2 | 100.0 |
Gonads/*embryology/metabolism | 2 | 66.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Receptor, IGF Type 1/metabolism | 2 | 6.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 2 | 1.0 |
Genomic Library | 2 | 0.0 |
Sarcoma, Ewing's/genetics/pathology | 2 | 40.0 |
Zinc Fingers/genetics/physiology | 2 | 28.0 |
Sex Determination (Analysis) | 3 | 10.0 |
WT1 Proteins/biosynthesis/*genetics | 3 | 100.0 |
Sertoli Cells/chemistry | 2 | 20.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 4 | 2.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
Kidney Neoplasms/genetics/*pathology | 3 | 25.0 |
Nephroblastoma/genetics/*pathology | 3 | 100.0 |
Antisense Elements (Genetics)/genetics | 2 | 18.0 |
DNA, Neoplasm/genetics | 14 | 1.0 |
Epithelium/embryology | 2 | 11.0 |
Genes, p53/genetics | 3 | 1.0 |
Protein p53/physiology | 2 | 2.0 |
Zinc Fingers/*physiology | 2 | 9.0 |
*Cloning, Molecular | 2 | 0.0 |
Iris/abnormalities | 2 | 66.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
*Xenopus Proteins | 2 | 0.0 |
*Chromosomes, Human, Pair 16 | 5 | 2.0 |
Bone Marrow | 2 | 5.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cell Survival/drug effects | 4 | 0.0 |
Gene Rearrangement | 5 | 1.0 |
Gene Dosage | 4 | 1.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Nephroblastoma/genetics/*metabolism | 2 | 50.0 |
Kidney/*growth & development | 2 | 50.0 |
Cell Division/drug effects/genetics | 2 | 2.0 |
Oligonucleotides, Antisense/genetics/*pharmacology | 2 | 15.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2 | 2 | 1.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
Mental Retardation/*genetics | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Genes, ras | 2 | 0.0 |
Gene Frequency | 4 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Transforming Growth Factor beta/*biosynthesis/genetics | 2 | 14.0 |
Cricetulus | 2 | 0.0 |
Cancer Vaccines/adverse effects/*genetics/*immunology/therapeutic use | 2 | 100.0 |
*Proto-Oncogenes | 3 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Macromolecular Substances | 4 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Insulin-Like Growth Factor II/biosynthesis | 3 | 60.0 |
Gene Expression Regulation, Neoplastic/*genetics | 9 | 4.0 |
Gene Expression Regulation, Neoplastic/physiology | 3 | 2.0 |
Xenopus laevis | 2 | 0.0 |
*Introns | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Osteosarcoma | 3 | 3.0 |
Nephroblastoma/metabolism | 3 | 75.0 |
*Genes, ras | 2 | 0.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Leukemia, Myelocytic, Acute/genetics | 2 | 6.0 |
DNA-Binding Proteins/biosynthesis/*metabolism | 2 | 3.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Transcription Factors/biosynthesis/*metabolism | 2 | 4.0 |
Testicular Neoplasms/*genetics | 2 | 8.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 4 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Mesothelioma/*genetics | 2 | 10.0 |
Lymphocyte Activation | 2 | 0.0 |
WT1 Proteins/*immunology | 4 | 100.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Open Reading Frames | 3 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Stem Cell Transplantation | 2 | 4.0 |
Hematopoiesis | 2 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Soft Tissue Neoplasms/*genetics | 2 | 7.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
Seminoma/genetics | 2 | 28.0 |
WT1 Proteins/*genetics/*physiology | 2 | 100.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
*Suppression, Genetic | 2 | 7.0 |
Retinoblastoma/genetics | 2 | 11.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Kidney Neoplasms/drug therapy/*genetics/pathology | 2 | 100.0 |
Nephroblastoma/drug therapy/*genetics/pathology | 2 | 100.0 |
Chromosomes, Human, Pair 11/*ultrastructure | 2 | 9.0 |
*Exons | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Kidney/chemistry | 2 | 4.0 |
Mesonephros/chemistry | 2 | 66.0 |
Kidney/*pathology | 2 | 3.0 |
Glycine | 2 | 2.0 |
Green Fluorescent Proteins | 2 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
TATA Box | 3 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Family | 3 | 0.0 |
DNA, Single-Stranded | 3 | 3.0 |
DNA, Neoplasm/genetics/isolation & purification | 3 | 2.0 |
*Urogenital Abnormalities | 6 | 50.0 |
Lac Operon | 2 | 1.0 |
Mice, Mutant Strains | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Methionine/metabolism | 2 | 1.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Bladder/pathology/physiology | 2 | 66.0 |
Colon/pathology/physiology | 2 | 66.0 |
DNA Restriction Enzymes/*genetics | 2 | 40.0 |
Digestive System/pathology | 2 | 33.0 |
Esophagus/pathology/physiology | 2 | 66.0 |
Mutagenicity Tests/*methods | 2 | 7.0 |
Precancerous Conditions | 2 | 11.0 |
Protein p53/*genetics | 2 | 1.0 |
Blast Crisis/genetics | 2 | 10.0 |
Drosophila Proteins/*genetics | 2 | 11.0 |
Laminin/analysis | 2 | 6.0 |
*Chromosome Disorders | 2 | 2.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
WT1 Proteins/metabolism/*physiology | 2 | 100.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
WT1 Proteins/*physiology | 3 | 100.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
Antigens, Neoplasm/immunology | 4 | 3.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Binding Sites, Antibody | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 2 | 1.0 |
Immunotoxins/*pharmacology | 4 | 9.0 |
Bone Marrow Examination | 2 | 5.0 |
Microfilament Proteins/metabolism | 2 | 2.0 |
T-Lymphocytes | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Membrane Proteins/*genetics/metabolism | 2 | 1.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Leukemia, Myeloid, Chronic/*therapy | 3 | 21.0 |
Leukemia, Lymphocytic/*immunology | 3 | 10.0 |
Cell Differentiation/*genetics | 2 | 2.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Antigen Presentation | 2 | 0.0 |
HLA-A2 Antigen/immunology | 2 | 5.0 |
Hungary | 2 | 3.0 |
Proto-Oncogene Protein c-kit/metabolism | 2 | 4.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Immunotherapy/methods | 2 | 2.0 |
Keratin/*metabolism | 2 | 6.0 |
